OCUL Ocular Therapeutix Corp: Enterprise Value to EBITDA Ratio

Ocular Therapeutix Corp - graphic logo of issuer OCUL

High patent barriers and FDA certifications protect the Ocular Therapeutix (OCUL) niche from competitors. The EV/EBITDA ratio of this capital-intensive business on the GURU.Markets chart demonstrates the asset's dynamics, where the 0.00 level captures the current state. The transition to recurring implant sales stabilizes cash flows, although geopolitical fragmentation and trade sanctions significantly hinder international ophthalmological research and equipment deliveries.

Ocular Therapeutix Corp - OCUL Company Value to EBITDA (period 11/23/2025 - 11/15/2026)

OCUL (Ocular Therapeutix, Inc.): analytical breakdowns and indicator data

- current price and projected stock value:
Analysis of all company metrics:Ocular Pharma (OCUL)
Original product of ocutx.com

The stable operation of Ocular Therapeutix (OCUL) production lines for ophthalmic implants, combined with an analysis of the company's EV/EBITDA multiple, allows for an assessment of capital capacity efficiency. The ratio of enterprise value to earnings before interest, taxes, depreciation, and amortization determines the business payback period, helping investors identify asset overvaluation or an optimal entry point prior to a growth phase.

Competitors of Ocular Therapeutix

Alcon Inc - Enterprise Value to EBITDA Ratio|Bausch + Lomb (BLCO) - Company Value to EBITDA|GKOS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Apellis|BLTE: EV/EBITDA Multiple|Company Value to EBITDA Harrow Corp (HROW)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization viridiantherapeutics.com|lenz-tx.com (LENZ) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple OCS|EYPT - Company Value to EBITDA|EV/EBITDA Multiple KOD (Kodiak Sciences Inc.)|Aldeyra - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KALA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Opus Genetics, Inc. IRD|okyopharma.com (OKYO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Adverum (ADVM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization outlooktherapeutics.com|CLSD: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio NBY (NovaBay Pharmaceuticals)|KPRX (Kiora Pharmaceuticals Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ALIM (Alimera Sciences Inc)|Total Company Value to Operating Income Before Depreciation Ratio Eyenovia Corp (EYEN)|GHSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Ocuphire Pharma, Inc.|opthea.com (OPT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization